Thermo Fisher grows into CGT manufacturing, while Samsung Biologics expands into ADCs
26 Oct 2023
ADC
Thermo Fisher and Samsung Biologics, which both have manufacturing capabilities, appear to have divergent approaches to recent service expansion plans. Thermo is leaning into new cell and gene therapy work, while Samsung is looking into antibody-drug conjugate expansion, according to their respective third-quarter earnings reports.
Thermo notably debuted several new CGT manufacturing services in the past few months. In June, the company introduced its next-generation platform of cell therapy reagents, dubbed Gibco CTS Detachable Dynabeads. It also launched its fill-finish service for biopharma and CDMO clients. That said, Thermo already has antibody production capabilities.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.